drugset / Trial / NCT00609921
A Phase 1 Study of ARQ 197 in Patients With Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, open label, dose escalation study of ARQ 197 in patients with advanced/recurrent solid tumors. The purpose of this study is to determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.
Timeline
- Start
- 2008-01
- Primary completion
- 2011-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tivantinib | Small molecule | — | — |